Luke Niforatos, executive vice president for Smart Approaches to Marijuana, earlier called more research into marijuana-based medications a “good thing.” But the group wants marijuana to stay right where it is, at Schedule 1.
“From a scientific perspective, (it) makes no sense to change,” he said. “What we’ve learned from the science … it’s not something that has medical value.”
Read the entire article here.